Heart doctors now see colchicine—a cheap pill long used for gout—as a real weapon against repeat heart problems. Major guidelines added it for secondary prevention after early wins, but newer studies mixed signals. 
This large review published in the Journal of Cardiovascular Drugs pooled all worldwide random trials comparing colchicine to placebo or usual care in patients with past heart attacks, strokes, or artery disease. The researchers covered 14 studies and 31,397 people, focusing on major adverse heart events like death, heart attack, stroke, or urgent procedures. Other endpoints included swelling marker C-reactive protein, single event types, deaths, and side effects. 
Heart Events Drop Across All CVD Cases
Colchicine cut major heart events overall by 20% with odds ratio 0.80 and range from 0.68 to 0.94. In fresh artery block cases, it worked even better at 28% drop, odds 0.72 from 0.60 to 0.86. This held true across races and settings.
Swelling Falls and Dose Makes Difference
C-reactive protein dropped a lot, proving colchicine lowers artery inflammation that induces clots. Benefits grew clear above 90 mg-days total—about 0.5 mg daily for six months—with 34% lower event odds from 0.52 to 0.84. Lower doses fell short.
No Death Risk and Few Extra Harms
Heart and total deaths stayed even between groups. Side effects like gut upset occurred but stayed manageable.
Easy Add-On for Clinic Use
Cardiologists gain a simple daily pill that can be used along with statins and blood thinners to fight leftover risk. Guidelines get firm backing for longer use in steady patients. Start at half milligram for months for improved outcomes.